AstraZeneca plc (AZN) Stock Rating Reaffirmed by JPMorgan Chase & Co.
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by JPMorgan Chase & Co. in a research note issued to investors on Monday.
Several other research analysts also recently commented on AZN. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,600 ($73.10) price target on shares of AstraZeneca plc in a report on Tuesday, June 14th. Jefferies Group raised their price target on shares of AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the company a “hold” rating in a report on Tuesday, June 14th. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a report on Tuesday, June 14th. BNP Paribas reissued an “outperform” rating and issued a GBX 5,000 ($65.27) price target on shares of AstraZeneca plc in a report on Wednesday, June 15th. Finally, HSBC reissued a “hold” rating and issued a GBX 4,240 ($55.35) price target on shares of AstraZeneca plc in a report on Friday, June 17th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc has an average rating of “Hold” and a consensus price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 0.29% during mid-day trading on Monday, reaching GBX 5101.00. The company had a trading volume of 969,714 shares. The firm’s market capitalization is GBX 64.53 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm has a 50-day moving average price of GBX 5,005.11 and a 200 day moving average price of GBX 4,435.88.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/astrazeneca-plc-azn-stock-rating-reaffirmed-by-jpmorgan-chase-co-3.html
The company also recently announced a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.